Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track
This article was originally published in The Gray Sheet
Executive Summary
Medtronic maintains that it will submit a PMA for the Endeavor drug-eluting stent on schedule, despite failing to meet its primary endpoint for in-segment late lumen loss in the ENDEAVOR III confirmatory study
You may also be interested in...
No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?
Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C
No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?
Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C
Boston Scientific Acquisition Vote Follows Week Of Bad News For Guidant
Boston Scientific and Guidant shareholders approved the merger of their companies in separate votes March 31, leaving U.S. and European antitrust clearances as the only remaining hurdles to closing the deal